Profusa, Inc. (PFSA)
| Market Cap | 167.73K -99.1% |
| Revenue (ttm) | n/a |
| Net Income | -36.56M |
| EPS | n/a |
| Shares Out | 46.60K |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 21,269 |
| Open | 3.688 |
| Previous Close | 0.951 |
| Day's Range | 3.449 - 3.688 |
| 52-Week Range | 0.806 - 1,297.503 |
| Beta | 0.49 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 21, 2026 |
About PFSA
Profusa, Inc., a digital health technology company, develops bioengineered sensors for body to detect and continuously transmit clinical-grade data for personal and medical use in the United States. It offers the Lumee Oxygen Platform to monitor compromised tissue for peripheral artery disease, chronic wounds, and reconstructive surgery. The company researches and develops the Lumee Glucose Platform which is designed to monitor glucose levels in interstitial fluid. Profusa, Inc. is based in Berkeley, California.
Financial Performance
Financial StatementsNews
Profusa announces 1-for-4 reverse stock split
Profusa (PFSA)announced that it led an amendment to its amended and restated certificate of incorporation with the Secretary of State of the State of Delaware to elect a one-for-four reverse…
Profusa Inc trading halted, news pending
19:50 EDT Profusa (PFSA)Inc trading halted, news pending
Profusa Announces 1-for-4 Reverse Stock Split
BERKELEY, California, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. (“Profusa” or the “Company”) (Nasdaq: PFSA), a commercial stage digital health company pioneering a next-generation technology pla...
Profusa Announces Signing of Option Agreement for the Acquisition of a Commercial Stage Diagnostics Company, G3 Vision Labs
BERKELEY, Calif., July 31, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. (Nasdaq: PFSA), a digital health company pioneering next-generation biosensing technologies, announces the signing of an Option Agreem...
Profusa to acquire diagnostics company, appoints Jack Stover CEO
Profusa (PFSA)signed a non-binding term sheet with a privately held, commercial-stage health diagnostics and toxicology testing company – the “Dx Company -. Following the contemplated transaction, the...
Profusa Announces Key Management Changes and Signing of Non-Binding Term Sheet for the Acquisition of a Commercial Stage Diagnostics Company
BERKELEY, Calif., July 27, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. (Nasdaq: PFSA), a digital health company pioneering next-generation biosensing technologies, announces the signing of a non-binding t...
Profusa Inc trading halted, news pending
19:50 EDT Profusa (PFSA)Inc trading halted, news pending
Profusa announces 1-for-25 reverse stock split
Profusa (PFSA)filed an amendment to its amended and restated certificate of incorporation with the Secretary of State of the State of Delaware to effect a one-for-twenty-five reverse stock split of…
Profusa Announces 1-for-25 Reverse Stock Split
BERKELEY, California, July 02, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. (“Profusa” or the “Company”) (Nasdaq: PFSA), a commercial stage digital health company pioneering a next-generation technology pla...
Profusa Shareholders Approve Strategic Initiatives at 2026 Annual Meeting, Supporting PanOmics Acquisition, Balance Sheet Strengthening and Nasdaq Compliance Efforts
BERKELEY, Calif., June 24, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. (Nasdaq: PFSA), a digital health company pioneering next-generation biosensing technologies, announces that shareholders approved all ...
Profusa Submits Response Package to GMED as Part of Ongoing CE Mark Review Process for Lumee® Oxygen Platform
BERKELEY, CA, June 12, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. (Nasdaq: PFSA), a digital health company pioneering next-generation biosensing technologies, today announces that it has submitted its res...
Profusa Issues Letter to Shareholders Encouraging Shareholders to Vote FOR All Proposals at June 23, 2026 Annual Meeting
BERKELEY, CA, June 10, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. (“Profusa” or the “Company”) (Nasdaq: PFSA), a leading digital health company pioneering next-generation biosensing technologies, today is...
Profusa to transfer listing to Nasdaq
Profusa (PFSA)announced that, effective May 15, the company will now be listed on Nasdaq.
Profusa Announces Listing Transfer to The Nasdaq Capital Market
BERKELEY, CA, May 15, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. (“Profusa” or the “Company”) (Nasdaq: PFSA), a digital health company pioneering the next generation of technology platform enabling the ...
Profusa receives favorable Nasdaq listing determination
Profusa (PFSA)announced that, by letter dated May 6, the Nasdaq Hearings Panel granted the company’s request to transfer the listing of its securities from The Nasdaq Global Market to The…
Profusa Receives Favorable Nasdaq Listing Determination
BERKELEY, CA, May 08, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. (“Profusa” or the “Company”) (Nasdaq: PFSA), a digital health company pioneering the next generation of technology platform enabling the c...
Profusa Initiates Board-Led Process to Evaluate Strategic Alternatives and Maximize Shareholder Value
Company focusing resources on near-term commercial milestones; European CE Mark process and Healthcare Research revenue opportunities Process intended to evaluate strategic growth alternatives to enha...
Profusa announces $30M letter of intent for PanOmics diagnostic platform
Profusa (PFSA)announced a strategic expansion into molecular diagnostics through a Letter of Intent to acquire the PanOmics multi-omics diagnostics platform from BioInsights. The company believes this...
Profusa Expands into Multi-Billion Dollar Precision Diagnostics Market with $30M Letter of Intent for a PanOmics Platform
Company secures scalable multi-omics diagnostics platform and launches Mayo Clinic partnership adding to Lumee real-time biochemistry monitoring platform to advance pancreatic cancer applications BERK...
Profusa To Withdraw S-1 Registration Statement to Pursue a Smaller, More Focused Offering
After Reevaluating its Near-term Capital Needs Given the Recent Changes in its Projected 2026 Revenue and Mayo Collaboration, the Company Determined that a $15 Million Offering is Not Required to Achi...
Profusa Receives Purchase Orders for Lumee™ Tissue Oxygen Monitoring and Raises 2026 Revenue Guidance
With strong underlying market demand, European distributor and expert physician customer purchase orders are being received by the Company as its 2026 revenue guidance range increases to $1.5 million ...
Profusa and Mayo Clinic collaborate to Advance High-Impact Clinical Applications of Oxygen Monitoring Technologies
Collaboration with Mayo Clinic aims to accelerate regulatory approval and commercialization of Lumee™ wearable continuous tissue oxygen monitoring product
Profusa Announces 1-for-75 Reverse Stock Split
BERKELEY, California, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. (“Profusa” or the “Company”) (Nasdaq: PFSA), a commercial stage digital health company pioneering a next-generation technology pla...
Profusa Presents Positive US-Study Clinical Results at Leipzig Interventional Course (LINC) 2026
Study conducted at US sites evaluates LumeeTM in peripheral artery disease (PAD) patients BERKELEY, Calif, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. (“Profusa” or the “Company”) (Nasdaq: PFSA), ...
Profusa Launches Lumee™ Tissue Oxygen Healthcare Research Offerings, Initiating First Commercial Revenue
Research-use-only offerings are commercially available, enabling immediate product and service revenue generation Targets the global CRO market of $47.9 billion in 2025 and growing at 7% CAGR BERKELEY...